Related Experiment Video
Updated: Aug 20, 2025
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Therapy with high-dose statins reduces soluble P-selectin: The impact on plasma fibrin clot properties
Jakub Siudut1, Joanna Pudło2, Małgorzata Konieczyńska3
1Department of Thromboembolic Disorders, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland; Krakow Center for Medical Research and Technologies, John Paul II Hospital, Krakow, Poland.
Insights
High-dose statin therapy significantly reduces soluble P-selectin (sP-selectin), a platelet activation marker, in coronary artery disease patients. This reduction is linked to improved fibrin clot properties, suggesting a reduced prothrombotic state.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Pharmacology
Background:
- Coronary artery disease (CAD) patients often exhibit altered platelet activation and fibrin clot properties, contributing to a prothrombotic state.
- Previous studies on statin effects on platelets in CAD have produced conflicting results.
- Soluble P-selectin (sP-selectin) is a key marker of platelet activation, and its role in CAD pathophysiology is significant.
Purpose of the Study:
- To investigate the impact of high-dose statin therapy on plasma sP-selectin levels in CAD patients.
- To determine if changes in sP-selectin influence fibrin clot properties, such as permeability and lysis time.
- To explore the relationship between statin-induced changes in sP-selectin and other cardiovascular risk markers.
Main Methods:
- A study involving 130 advanced CAD patients with suboptimal LDL cholesterol control on statins.
- Measurement of plasma sP-selectin, fibrin clot permeability (Ks), clot lysis time (CLT), thrombin generation, and fibrinolysis proteins at baseline and after 6-12 months of high-dose atorvastatin or rosuvastatin.
- Statistical analysis to assess correlations between sP-selectin, fibrin clot properties, and lipid profiles.
Main Results:
- Baseline sP-selectin levels were associated with unfavorable fibrin clot properties (lower Ks, longer CLT) independent of lipid profiles.
- High-dose statin therapy led to a significant 32% reduction in plasma sP-selectin levels (p < 0.001).
- On-treatment changes in sP-selectin correlated with improvements in fibrin clot permeability and lysis time, but not with reductions in cholesterol or C-reactive protein.
Conclusions:
- High-dose statin therapy effectively reduces platelet activation, as indicated by decreased sP-selectin levels.
- The observed improvement in fibrin clot phenotype suggests that statins exert antithrombotic effects beyond lipid-lowering.
- Platelet-derived proteins like sP-selectin play a crucial role in the prothrombotic state of hypercholesterolemia, and statins can modulate this risk.
Objective:
Studies on the effect of statins on platelets in patients with coronary artery disease (CAD) yielded inconsistent results. We sought to investigate whether high-dose statin therapy reduces plasma concentrations of soluble P-selectin (sP-selectin), a well-established platelet activation marker and if such changes can affect fibrin clot properties, which are unfavorably altered in CAD patients.
Methods:
We studied 130 consecutive patients with advanced CAD who did not achieve the target LDL cholesterol on statins. At baseline and after 6-12 months of treatment with atorvastatin 80 mg/day or rosuvastatin 40 mg/day, soluble plasma sP-selectin, along with plasma fibrin clot permeability (Ks), clot lysis time (CLT), thrombin generation and fibrinolysis proteins were determined.
Results:
Before high-intensity statin treatment, lower Ks and longer CLT values were associated with increased sP-selectin (β -0.27 [95% CI -0.44 to -0.10] and β 0.21 [95% CI 0.01 to 0.41]; both p < 0.05, respectively) also after adjustment for potential confounders. sP-selectin, alongside fibrin features and other variables at baseline showed no association with lipid profile. On high-dose statin therapy, there was 32% reduction in sP-selectin levels (p < 0.001). On-treatment change (Δ) in sP-selectin correlated with ΔKs and ΔCLT (r = -0.32, p < 0.001 and r = 0.22, p = 0.011, respectively), but not with cholesterol and C-reactive protein lowering. We did not observe any associations between post-treatment sP-selectin levels and lipids, fibrin clot properties or thrombin generation.
Conclusions:
High-dose statin therapy reduces markedly sP-selectin levels in association with improved fibrin clot phenotype, which highlights the contribution of platelet-derived proteins to a prothrombotic state in hypercholesterolemia and statin-induced antithrombotic effects.
Related Concept Videos
01:16Clot Retraction and Fibrinolysis
01:17Intracellular Signaling Affects Focal Adhesions
Some...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents